Genomic Sequencing Examination of 733 HER2-amplified Key and metastatic breast tumours discovered significant enrichment of mutations that activate RAS–MAPK signalling in Superior tumours dealt with with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. In BC, pCR immediately after https://www.directivepublications.org/journal-of-clinical-breast-cancer/